EVALUATION OF THE EFFICACY OF ANTIVIRUS DRUGS IN CHRONIC DELTA HEPATITIS

Abstract

The value of efficiency of PEG-IFN-alfa 2-b Algeron was represented in combination with the analogy of nucleoside Tenofovir alafenamide (TAF) in therapy of CHDV during 6 months in 50 patients. The diagnosis of the disease was determined through revealing markers of hepatitis B and hepatitis D – HbsAg, HBV-DNA, anti- delta, HDV-RNA in ELISA and PCR in patients. The activeness of pathological process in liver was revealed with the help of aminotransferases test. The stage of illness was established through liver Fibro scanning. Algeron was prescribed in dose of 1,5 mcg/kg/week in combination with TAF in 25 mg/day. The efficiency of this scheme was tested after 4 injections (after 1 month from the beginning of the treatment), then after 3 and 6 months. The second group of 30 patients with same diagnosis were given TAF with 25 mg/day for 2 years. After 3 and 6 months from the beginning of the therapy the viral load (VL) of delta virus was examined. Significant decreases of VL were established in all periods of observation. After 3 months HDV in 28,9 of patients became undetectable. Other percentage of patients had deceased VL (2000-3000 IU/mg), but it did not disappear. Because of decrease of VL the level of aminotransferases and the level of fibrosis decreased respectively. Long-term use of the given scheme of therapy is more appropriate. In the second group of patients TAF monotherapy caused insignificant decrease of BH, often increasing in 3 months, then, small decline of BP is noted to the 6th month of the therapy. This is apparently - self healing, rather than TAF effect.